DDInter1261 DDInter1658
Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ulipristal
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Neratinib
Naloxegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Griseofulvin
Naloxegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Naloxegol {u} may lead to a major life threatening interaction when taken with {v} Conivaptan
Naloxegol {u} may lead to a major life threatening interaction when taken with {v} Stiripentol
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Naloxegol may lead to a major life threatening interaction when taken with Conivaptan
Naloxegol may lead to a major life threatening interaction when taken with Stiripentol